Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

Stroke

AI

The Impact of Automated Software on Alberta Stroke Program Early CT Score

The Alberta Stroke Program Early CT Score (ASPECTS) is essential for clinical decision-making when treating ischemic stroke patients. It helps measure early ischemic changes and predict the functional outcome of endovascular thrombectomy.
featured-image

Aneurysm

AI

Advanced Imaging

Funding brain aneurysm research: Q&A with Christine Buckley of the Brain Aneurysm Foundation

RapidAI is proud to partner with the Brain Aneurysm Foundation (BAF) and support its mission to promote early detection of brain aneurysms by raising awareness of the signs, symptoms, and risk factors.
featured-image

Stroke

AI

Advanced Imaging

Neurovascular imaging for patients with suspected transient ischemic attack

Approximately 240,000 people in the United States experience a transient ischemic attack (TIA) annually. A TIA is a stroke lasting only a few minutes when the blood supply to part of the brain is briefly interrupted.
featured-image

Stroke

Workflow

AI

Mastering the Art of Patient Transfer: Utilizing RapidAI Software for Seamlessly Transferring Patients to a Different Hospital

Neuroimaging has played a significant role in the stroke workflow following the DAWN and DEFUSE 3 trials and revised guidelines for acute ischemic stroke treatment. It helps determine which patients are eligible for endovascular thrombectomy (EVT) in the late window.
featured-image

Stroke

AI

Advanced Imaging

Optimal patient selection for endovascular thrombectomy procedure: CT Perfusion versus Non-contrast CT

Landmark stroke clinical trials DAWN and DEFUSE 3 helped validate the benefits of endovascular thrombectomy (EVT) procedure in acute ischemic stroke patients (AIS) in the late window. CT perfusion (CTP) aided in selecting eligible patients with a favorable perfusion profile.
featured-image

Stroke

AI

Neuroprotectant ApTOLL reduced death and disability in acute ischemic stroke patients

ApTOLL, a neuroprotective agent, has shown promising results in the APRIL 1b/2a trial and reduced death and disability when used alongside standard treatment in selected ischemic stroke patients. Rapid CTP helped with patient selection and mismatch determination.
featured-image

Aneurysm

AI

Genetics of brain aneurysms

A brain aneurysm is a weak or thin spot in the blood vessel wall, which may balloon and fill with blood. An estimated 6.5 million people in the United States have an unruptured brain aneurysm, of which 30,000 rupture each year. A ruptured aneurysm can cause serious health problems like hemorrhagic stroke, brain damage, and even death.
featured-image

Stroke

AI

Advanced Imaging

A recap of key results from RapidAI’s 2022 publications

In 2022, the RapidAI clinical affairs team partnered with physicians across therapeutic areas to help advance research and improve patient outcomes.
featured-image

Stroke

AI

Advanced Imaging

Sex differences in WAKE-UP stroke trial

Sex-based differences have been reported in stroke settings. Women often present with more severe stroke symptoms. They may also experience treatment delays despite no differences in treatment eligibility.
1 2 3